对特纳等人就赞纳德等人关于评估治疗糖尿病新药的心血管风险：风险评估与风险规避的社论所做评论的回应 - Suppr

Suppr

超能文献

Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

作者信息

Zannad Faiez

机构信息

Inserm CIC 1433, Université de Lorraine, CHU Cardiology, 4, rue du Morvan, 54500 Vandoeuvre-les-Nancy, France.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):131. doi: 10.1093/ehjcvp/pvx012.

DOI:10.1093/ehjcvp/pvx012

PMID:28541522

Abstract

摘要

相似文献

Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):131. doi: 10.1093/ehjcvp/pvx012.

Response to the 'Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.'.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):130. doi: 10.1093/ehjcvp/pvx011.

Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):129. doi: 10.1093/ehjcvp/pvx006.

With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion.

Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):7-8. doi: 10.1093/ehjcvp/pvw023. Epub 2016 Aug 22.

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.

Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5. doi: 10.1093/ehjcvp/pvw007. Epub 2016 Apr 3.

Comment on Li et al. Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes. Diabetes Care 2023;46:425-433.

Diabetes Care. 2024 Mar 1;47(3):e31. doi: 10.2337/dc22-2466.

Response to Comment on Cheng et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care 2018;41:2306-2315.

Diabetes Care. 2019 Apr;42(4):e63. doi: 10.2337/dci18-0057.

Comment on Cheng et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care 2018;41:2306-2315.

Diabetes Care. 2019 Apr;42(4):e62. doi: 10.2337/dc18-2175.

Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430.

Diabetes Care. 2016 Oct;39(10):e190-1. doi: 10.2337/dci16-0023.

Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".

Circulation. 2019 Oct 15;140(16):e724-e725. doi: 10.1161/CIRCULATIONAHA.119.042457. Epub 2019 Oct 14.

引用本文的文献

Chronic kidney disease impairs prognosis in electrical storm.

J Interv Card Electrophysiol. 2022 Jan;63(1):13-20. doi: 10.1007/s10840-020-00924-6. Epub 2021 Jan 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

作者信息

Zannad Faiez

机构信息

Inserm CIC 1433, Université de Lorraine, CHU Cardiology, 4, rue du Morvan, 54500 Vandoeuvre-les-Nancy, France.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):131. doi: 10.1093/ehjcvp/pvx012.

DOI:10.1093/ehjcvp/pvx012

PMID:28541522

Abstract

摘要